Skip to main content

Market Overview

Cocrystal Pharma Stock Is Trading Higher After COVID-19 Candidate Shows Preclinical Activity Against Delta, Gamma Variants

Share:
Cocrystal Pharma Stock Is Trading Higher After COVID-19 Candidate Shows Preclinical Activity Against Delta, Gamma Variants
  • Cocrystal Pharma Inc (NASDAQ: COCP) announces that its SARS-CoV-2 3CL protease lead CDI-45205 and several analogs showed potent in vitro activity against the SARS-CoV-2 Delta (India/B.1.617.2) and Gamma (Brazil/P.1) variants. 
  • "Our next steps are to scale-up synthesis and manufacture active pharmaceutical ingredient (API) to support Investigational New Drug (IND)-enabling studies to advance CDI-45205 into clinical trials," said James Martin, CFO, and interim co-CEO.
  • Last month, the Company announced CDI-45205, and its analogs showed robust antiviral activity against the alpha & beta variants, surpassing the activity observed with the original Wuhan strain.
  • Price Action: COCP shares are up 20% at $1.32 during the market session on the last check Thursday.
 

Related Articles (COCP)

View Comments and Join the Discussion!

Posted-In: Biotech Long Ideas News Penny Stocks Health Care Movers Trading Ideas General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com